Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CombiRx: Interferon beta-1a and Glatiramer Acetate in RRMS
NCT00211887Phase 3Completed
- Sponsor
- Fred Lublin
- Start
- Jan 2005
- Primary completion
- Apr 2012
- Modality
- Cytokines & Interferons, Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Fred Lublin. Started Jan 2005; status: completed.
02
Drugs
interferon beta-1aglatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00211887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211887.